Citations

Clear

350 citation(s) found for "Stevens, V".

Controversies in the Management of Central Nervous System Coccidioidomycosis
Ampel, Neil M. , Blair, Janis E. , Donovan, Fariba , Fierer, Joshua , Galgiani, John N. , Heidari, Arash , Johnson, Royce H. , Shatsky, Stanley A., Uchiyama, Christopher M. , Stevens, David A. , Thompson, George R

Mayo Clinic

Clinical Infectious Diseases | June 19, 2022 | Volume: 75 | Issue: 4 | Pages: 555-559

10.1093/cid/ciac478 | PMID 35717645 Get It

Abstract Central nervous system infection with Coccidioides spp. is fatal if untreated and complications occur even when therapy is directed by experienced clinicians. We convened a panel of clinicians experienced in the management of coccidioidal meningitis to summarize current controversies and provide consensus for the management of this difficult infection.
Implementing SAFER Responses to Misconduct and Responding to Biased Patient Requests ASAP
Stevens, Sheila K., Houge, Benjamin J., Poterucha, Jeff M, Preston, Heather R., Werneburg, Brooke L., Welch, Thomas J, Siddiqui, Mustaqeem , Siddiqui, Mustaqeem A , Welch, Thomas

Mayo Clinic

Journal of Patient Experience | June 8, 2022 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/23743735221102672 | PMID 35694012 Get It

Background: In response to encounters involving misconduct, discrimination, and harassment toward healthcare workers, the Experience Training, Education, and Coaching (XTEC) team was tasked with empowering staff members to respond to biased requests and misconduct appropriately and consistently. The aim of this article is to discuss communication strategies for how to respond to patient bias and misconduct. Methods: XTEC developed a training program with two focused communication strategies: (1) SAFER, a stepped approach to respond to patient and visitor misconduct and (2) ASAP, an approach for responding to patient bias which we describe as requests related to race, religion, ethnicity, gender, and other personal attributes of staff. Intervention: SAFER ASAP workshops were delivered to 2154 health care professionals through 109 face-to-face training over a 15-month period between January 2019 and March 2020. All trainings were discussion- and scenario-based, ranging in duration from 60 to 90 min. Participants were given pre- and post-training test case scenarios, in which respondents wrote responses to a challenging behavior to assess skill attainment post-training. Results:Seventy-one percent demonstrated higher levels of response ability post-training, and 92% of respondents indicated they would likely recommend this training to others. Conclusions: SAFER ASAP is an effective communication training program for responding to patient and visitor bias and misconduct.
Pharmacokinetics (PK) and pharmacodynamics (PD) in First-MIND: A phase Ib, open-label, randomized study of tafasitamab (tafa) ± lenalidomide (LEN) in addition to R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Kopečková, Kateřina , Burgués, Juan Miguel Bergua, Stevens, Don A., Nowakowski, Grzegorz S. , Waldron-Lynch, Maeve, Hadar, Nira, Weirather, Johannes, Lässig, Charlotte , Blair, Derek, Dreyling, Martin , Belada, David

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: e19553-e19553

10.1200/jco.2022.40.16_suppl.e19553 Get It

e19553 Background: The combination of tafa + LEN has accelerated approval in the United States (2020) and conditional approval in Canada and Europe (2021) for R/R DLBCL in ASCT-ineligible adult pts. A tolerable safety profile for R-CHOP + tafa ± LEN in pts with newly diagnosed DLBCL in the Phase Ib First-MIND study (NCT04134936) was previously reported, with numerically superior efficacy for R-CHOP + tafa + LEN (ASH 2021; #3556). We report PK, PD, and immunogenicity of R-CHOP + tafa ± LEN in this first line setting. Methods: Eligible pts ≥18 years with treatment-naïve DLBCL, IPI 2–5, and ECOG PS 0–2 were randomized 1:1 to either six 21-day (D) cycles (C) of R-CHOP (R-CHO, D1; P, D1–5) + tafa (12 mg/kg IV, D1, 8, 15) (Arm A) or R-CHOP + tafa + LEN (25 mg orally, D1–10) (Arm B). Secondary endpoints included tafa serum conc and number and percentage of pts developing anti-tafa Abs. Exploratory endpoints included natural killer (NK) cell, T-cell, and B-cell count in peripheral blood. Results: Data cut-off: 13 March 2021 for safety analysis, incl. ≥1 month follow-up after EoT visit for all pts; 15 September 2021 for efficacy. Tafa serum conc reached steady state by C3 (geometric mean trough conc: Arm A, 186.40–216.55 µg/mL; Arm B, 171.77–201.54 µg/mL) and steadily declined after treatment completion. Anti-tafa Abs were detected in 1/65 (1.5%) pts. This pt showed pre-existing tafa Abs at baseline, which decreased during treatment. Median NK cell count decreased from baseline at C1D8 but was at baseline or higher levels by EoT visit (Arm A) and C1D15 (Arm B; Table). T-cell count decreased from baseline at C1D8 in both arms but was at baseline level or higher by C1D15 (Arm A) and EoT visit (Arm B). Median B-cell count decreased from baseline to 0 cells/μL (Arm A, C1D15; Arm B, C1D8); at 6-month follow-up after EoT visit, B-cell count had recovered to measurable levels in ̃50% of pts. Conclusions: Tafa serum conc reached and maintained a therapeutic dose level in this first-line regimen and declined in line with known tafa half-life (̃16 days) after treatment completion; tafa levels were comparable between the two treatment arms. No pt developed treatment-induced or treatment-boosted anti-tafa Abs. Median NK-cell, T-cell, and B-cell counts were comparable between treatment arms in all cycles. Clinical trial information: NCT04134936. [Table: see text]
Availability of data for screening, offering, and consenting patients to cancer clinical trials: Report from an ASCO-ACCC collaboration.
Pressman, Alice , Hurley, Patricia A. , Kaltenbaugh, Melinda , Bernick, Lea Ann, Byatt, Leslie, Crews, Jennie R. , McCaskill-Stevens, Worta J., Nowakowski, Grzegorz S. , Oyer, Randall A. , Patel, Manali I. , Pierce, Lori J. , Williams, Jen Hanley, Zwicker, Victoria, Hurley, Patricia , Bruinooge, Suanna S. , Garrett‐Mayer, Elizabeth , Boehmer, Leigh , Charlot, Marjory , Fashoyin-Aje, Lola , Ramirez, Amelie G , Guerra, Carmen E.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 6530-6530

10.1200/jco.2022.40.16_suppl.6530 Get It

6530 Background: Only a small fraction of patients with cancer participate in treatment trials. Patients identifying as members of racial and ethnic minority groups are consistently underrepresented in these trials. A recent systematic review reported that patients, regardless of race and ethnicity, are willing to enroll in trials if asked to participate by their treating clinician. Prospective and longitudinal data and metrics at the site- and clinician-level are necessary to understand whether patients are equitably considered for clinical trials. Methods: ASCO and Association of Community Cancer Centers (ACCC) developed a self-assessment for trial sites to record and gauge the number of patients across races and ethnicities screened, offered, and enrolled into clinical trials. Research sites, from across the US, were recruited through an open call to apply to participate in the ASCO-ACCC Pilot Project. There were 65 sites assigned to this pilot study, which tested the feasibility and utility of the site assessment. Sites were asked to enter 2019 and 2020 aggregate data for each step along the clinical trial enrollment continuum by select races and ethnicities (Black, Hispanic/Latinx, White) and overall. Results: 62 of 65 sites completed the study and represented a range of settings and practice types (61% academic, 26% hospital/health system, 13% independent). Only 2 sites (3%) were able to provide the data requested at each enrollment step in the assessment (table). Sites that collected the data did not do so routinely (table) and most had to compile data through multiple sources and/or manual extraction (40-100% across enrollment steps). Sites with missing data reported they did not collect data at all (36-64% across enrollment steps), did not collect data in a systematic way (0-29% across enrollment steps), or stated it would be too burdensome to manually review charts to extract data (12-29% across enrollment steps). Conclusions: Data collection and routine evaluation of participation metrics, by race and ethnicity, are necessary to assess and monitor equity and diversity in clinical trials. Most sites in this study did not collect, or routinely collect, data for screening, offering, and consenting patients to clinical trials. Without these data, sites are unable to evaluate and monitor whether their patients have equitable access to clinical trials or establish strategies to address any inequities. ASCO and ACCC will continue to partner with sites to better understand their processes and the feasibility of collecting such data in a systematic and automated way, such as through electronic health record systems. [Table: see text]
Trends and Disparities in Access to Buprenorphine Treatment Following an Opioid-Related Emergency Department Visit Among an Insured Cohort, 2014-2020
Stevens, Maria , Tsai, Jennifer , Nath, Bidisha , Melnick, Edward R. , D’Onofrio, Gail , Jeffery, Molly M. , Stevens, Maria A, Savitz, Samuel T. , Jeffery, Molly Moore , Melnick, Edward R

Mayo Clinic

JAMA Network Open | June 3, 2022 | Volume: 5 | Issue: 6 | Pages: e2215287

10.1001/jamanetworkopen.2022.15287 | PMID 35657629 Get It

Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement
Oyer, Randall A. , Hurley, Patricia A. , Boehmer, Leigh , Bruinooge, Suanna S. , Levit, Kathryn , Barrett, Nadine J. , Benson, Al B. , Bernick, Lea Ann, Byatt, Leslie, Charlot, Marjory , Crews, Jennie R. , DeLeon, Kyle, Green, Sybil, Guerra, Carmen E. , Hamroun, Leila, Hardy, Claudia M. , Hempstead, Bridgette, Jeames, Sanford , Mann, Mel , Matin, Khalid , McCaskill‐Stevens, Worta , Merrill, Janette K. , Nowakowski, Grzegorz S. , Patel, Manali I. , Pressman, Alice , Segura, Juanita, Segarra-Vasquez, Barbara, Williams, Jen Hanley, Williams, J.E. Caerwyn , Winkfield, Karen M. , Yang, Eddy S. , Zwicker, Victoria, Pierce, Lori J. , Hurley, Patricia , Bruinooge, Suanna Steeby , Barrett, Nadine , Benson, Al , Fashoyin-Aje, Lola , Garrett-Mayer, Elizabeth , Gralow, Julie R , Guerra, Carmen E , Jeames, Sanford , Mann, Mel , Merrill, Janette , Nowakowski, Grzegorz S , Patel, Manali I , Pressman, Alice , Ramirez, Amelie G , Hanley Williams, Jen , Williams, James E , Winkfield, Karen M , Yang, Eddy S , Pierce, Lori J , Charlot, Marjory , Oyer, Randall A , Garrett‐Mayer, Elizabeth , Gralow, Julie R. , Segarra-Vasquez, Barbara

Mayo Clinic

Journal of Clinical Oncology | May 19, 2022 | Volume: 40 | Issue: 19 | Pages: 2163-2171

10.1200/jco.22.00754 | PMID 35588469 Get It

A concerted commitment across research stakeholders is necessary to increase equity, diversity, and inclusion (EDI) and address barriers to cancer clinical trial recruitment and participation. Racial and ethnic diversity among trial participants is key to understanding intrinsic and extrinsic factors that may affect patient response to cancer treatments. This ASCO and Association of Community Cancer Centers (ACCC) Research Statement presents specific recommendations and strategies for the research community to improve EDI in cancer clinical trials. There are six overarching recommendations: (1) clinical trials are an integral component of high-quality cancer care, and every person with cancer should have the opportunity to participate; (2) trial sponsors and investigators should design and implement trials with a focus on reducing barriers and enhancing EDI, and work with sites to conduct trials in ways that increase participation of under-represented populations; (3) trial sponsors, researchers, and sites should form long-standing partnerships with patients, patient advocacy groups, and community leaders and groups; (4) anyone designing or conducting trials should complete recurring education, training, and evaluation to demonstrate and maintain cross-cultural competencies, mitigation of bias, effective communication, and a commitment to achieving EDI; (5) research stakeholders should invest in programs and policies that increase EDI in trials and in the research workforce; and (6) research stakeholders should collect and publish aggregate data on racial and ethnic diversity of trial participants when reporting results of trials, programs, and interventions to increase EDI. The recommendations are intended to serve as a guide for the research community to improve participation rates among people from racial and ethnic minority populations historically under-represented in cancer clinical trials. ASCO and ACCC will work at all levels to advance the recommendations in this publication.
Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline
Schiff, David , Messersmith, Hans , Brastianos, Priscilla K. , Brown, Paul D. , Burri, Stuart H., Dunn, Ian F. , Gaspar, Laurie E., Gondi, Vinai , Maués, Julia , Mohile, Nimish, Redjal, Navid , Stevens, Glen , Bent, Martin J. van den , Wallace, H. James , Zadeh, Gelareh , Vogelbaum, Michael A. , Schiff, David , Jordan, Justin T , Maues, Julia , Redjal, Navid , Stevens, Glen , Sulman, Erik P , van den Bent, Martin J , Wallace, H James , Vogelbaum, Michael A , Messersmith, Hans , Jordan, Justin T. , Sulman, Erik P.

Mayo Clinic

Journal of Clinical Oncology | May 13, 2022 | Volume: 40 | Issue: 20 | Pages: 2271-2276

10.1200/jco.22.00333 | PMID 35561283 Get It

PURPOSE American Society of Radiation Oncology (ASTRO) has developed a guideline on appropriate radiation therapy for brain metastases. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS “Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline” 2 was reviewed for developmental rigor by methodologists. An ASCO Endorsement Panel subsequently reviewed the content and the recommendations. RESULTS The ASCO Endorsement Panel determined that the recommendations from the ASTRO guideline, published May 6, 2022, are clear, thorough, and based upon the most relevant scientific evidence. ASCO endorses “Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline.” 2 RECOMMENDATIONS Within the guideline, stereotactic radiosurgery (SRS) is recommended for patients with Eastern Cooperative Oncology Group performance status of 0-2 and up to four intact brain metastases, and conditionally recommended for patients with up to 10 intact brain metastases. The guideline provides detailed dosing and fractionation recommendations on the basis of the size of the metastases. For patients with resected brain metastases, radiation therapy (SRS or whole-brain radiation therapy [WBRT]) is recommended to improve intracranial disease control; if there are limited additional brain metastases, SRS is recommended over WBRT. For patients with favorable prognosis and brain metastases ineligible for surgery and/or SRS, WBRT is recommended with hippocampal avoidance where possible and the addition of memantine is recommended. For patients with brain metastases, limiting the single-fraction V 12Gy to brain tissue to ≤ 10 cm 3 is conditionally recommended. Additional information is available at www.asco.org/neurooncology-guidelines .
Antimicrobial Susceptibility of Elizabethkingia Species: Report from a Reference Laboratory
Comba, Işın Y. , Schuetz, Audrey N. , Misra, Anisha , Friedman, Daniel , Patel, Robin , Lancaster, Zane D., Shah, Aditya , Friedman, Daniel Z P , Stevens, Ryan, Patel, Robin , Schuetz, Audrey N , Comba, Isin Y , Stevens, Ryan W.

Mayo Clinic

Journal of Clinical Microbiology | May 5, 2022 | Volume: 60 | Issue: 6 | Pages: No page available

10.1128/jcm.02541-21 | PMID 35510517 Get It

Elizabethkingia species are Gram-negative bacilli that were most recently linked to a cluster of infections in the Midwestern United States from 2016 to 2017. Inappropriate empirical and directed antibiotic selection for this organism is common among providers and is an independent risk factor for mortality.
A research agenda to support the development and implementation of genomics-based clinical informatics tools and resources
Wiley, Ken, Findley, Laura, Goldrich, Madison P., Rakhra-Burris, Tejinder, Stevens, Ana, Bult, Carol J. , Deverka, Patricia A. , Green, Eric D. , Jarvik, Gail P. , Ramos, Erin M. , Relling, Mary V. , Roden, Dan M. , Rowley, Robb , Alterovitz, Gil , Aronson, Samuel , Bastarache, Lisa , Jeff, Janina M., Madhavan, Subha , Mendonça, Eneida A. , Ohno‐Machado, Lucila , Ritchie, Marylyn D. , Walton, Nephi , Zayas‐Cabán, Teresa, Manolio, Teri A. , Bult, Carol J , Roden, Dan M. , Cimino, James J , Del Fiol, Guilherme , Hoffman, Mark A , Kawamoto, Kensaku , Jarvik, Gail P , Williams, Pamela, Chisholm, Rex L. , Ginsburg, Geoffrey S. , Mensah, George A. , Cimino, James J. , Crowgey, Erin L. , Fiol, Guilherme Del , Freimuth, Robert R. , Hoffman, Mark A. , Johnson, Kevin B. , Pratap, Siddharth , Taylor, Casey Overby , Weng, Chunhua , Williams, Marc S

Mayo Clinic

Journal of the American Medical Informatics Association | April 14, 2022 | Volume: 29 | Issue: 8 | Pages: 1342-1349

10.1093/jamia/ocac057 | PMID 35485600 Get It

Abstract Objective The Genomic Medicine Working Group of the National Advisory Council for Human Genome Research virtually hosted its 13th genomic medicine meeting titled “Developing a Clinical Genomic Informatics Research Agenda”. The meeting’s goal was to articulate a research strategy to develop Genomics-based Clinical Informatics Tools and Resources (GCIT) to improve the detection, treatment, and reporting of genetic disorders in clinical settings. Materials and Methods Experts from government agencies, the private sector, and academia in genomic medicine and clinical informatics were invited to address the meeting's goals. Invitees were also asked to complete a survey to assess important considerations needed to develop a genomic-based clinical informatics research strategy. Results Outcomes from the meeting included identifying short-term research needs, such as designing and implementing standards-based interfaces between laboratory information systems and electronic health records, as well as long-term projects, such as identifying and addressing barriers related to the establishment and implementation of genomic data exchange systems that, in turn, the research community could help address. Discussion Discussions centered on identifying gaps and barriers that impede the use of GCIT in genomic medicine. Emergent themes from the meeting included developing an implementation science framework, defining a value proposition for all stakeholders, fostering engagement with patients and partners to develop applications under patient control, promoting the use of relevant clinical workflows in research, and lowering related barriers to regulatory processes. Another key theme was recognizing pervasive biases in data and information systems, algorithms, access, value, and knowledge repositories and identifying ways to resolve them.